ClinicalTrials.gg
CompletedNCT01484145Updated Oct 19, 2012

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

A Phase 2 interventional study of Terbinafine HCl in Onychomycosis, sponsored by Nitric BioTherapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-10-19.

Sponsored by Nitric BioTherapeutics, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Enrollment
17th of 19
25 · median 100
Started
2011
the only one that year
Phase 2
5 of 20
1 open now
Registered
10th of 20
by date
Lead sponsor
2 of 20
Nitric BioTherapeutics, Inc

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2011, is one of 5 in phase 2, and was the 10th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

The purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel. Iontophoretic delivery involves the use of a small electric charge to deliver drug across skin and nails.

03

Conditions studied

  • Onychomycosis

Browse trials for

Keywords

  • Onychomycosis
  • Nail fungus
  • Tinea Unguium
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive KOH
  • 25-75% involvement of the visible nail.
  • Nail plate must be \< 3 mm thick.
  • Must have signed .
  • Must agree to avoid any type of pedicure or application of any nail polish product or nail cosmetic to the toenails after the screening visit until Day 28.
  • Female subjects of must agree to take measures to avoid pregnancy until the day after Day 28
  • Must agree to avoid the use of oral antifungals or topical terbinafine anywhere on the body until the day after Day 28. Topical antifungals other than terbinafine can be used on the body other than the feet after Day 0.

Exclusion criteria

Exclusion Criteria:

  • Presence of proximal subungual onychomycosis or white superficial onychomycosis
  • Fungal involvement of a majority of the lunula
  • Subjects with psoriasis, eczema, or other abnormalities that could result in a clinically abnormal nail
  • Presence of dermatophytoma or onychomycotic spikes or exclusively lateral groove involvement
  • Traumatized or dystrophic target great toenail.
  • Known diabetics
  • Subjects with peripheral vascular disease
  • Subjects who are (chronic therapy, solid organ or bone marrow transplantation, cytotoxic chemotherapy within the previous 12 months (or planned within the next 12 months), or infection.
  • Use of systemic corticosteroids within 30 days preceding Day 0
  • Use of topical antifungals on the feet in the preceding 30 days of Day 0 through Day 28
  • Use of topical terbinafine in the 30 days prior to treatment through Day 28
  • Use of systemic antifungals in the preceding 120 days of Day 0 through Day 28
  • Use of any drug(s) within 30 days (120 days for systemic antifungals) preceding Day 0 through Day 28
  • Has previously participated in this study
  • Is pregnant or is a nursing mother
  • Women of of child bearing potential who are not using an adequate form of (or abstinence)
  • Subjects with pacemakers/automatic implantable cardioverter/defibrillators
  • Subjects with an implantable electronic device.
  • Subjects with a bleeding disorder or who are using warfarin or any other blood coagulation modulator including aspirin in the 14 days prior to treatment through Day 28
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    6 mA.min, 20 mins

    Drug: Terbinafine HCl

  • Experimental
    6 mA/min, 20 mins, clamping

    Drug: Terbinafine HCl

  • Experimental
    6 mA/min, 20 mins, debridement, clamping

    Drug: Terbinafine HCl

  • Experimental
    15 mA/min, 30 mins, clamping

    Drug: Terbinafine HCl

  • Experimental
    15 mA/min, 50 mins, debridement, clamping

    Drug: Terbinafine HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Level of terbinafine in the nail bed (ng/mg)

    Time frame: Day 28

  2. Plasma terbinafine levels (ng/ml)

    Time frame: Day 28

Secondary outcomes

  1. Number of treatment emergent adverse events (AEs)& Serious Adverse Events (SAEs)

    Time frame: 60 days

07

Study locations

1 site
  • Cetero Research
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Mar 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2011
First posted
Dec 2, 2011
Start
Dec 2011
Primary completionActual
Mar 2012
CompletionActual
Apr 2012
Last update
Oct 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01484145
Lead sponsor
Nitric BioTherapeutics, Inc
Responsible party
Sponsor
First posted
Dec 2, 2011
Start date
Dec 2011
Primary completion
Mar 2012
Completion
Apr 2012
Last update
Oct 19, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion